Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents
10.4306/jknpa.2022.61.3.224
- Author:
Chan-Mo YANG
1
;
Won-Myong BAHK
;
Young Sup WOO
;
Jong-Hyun JEONG
;
Jeong Seok SEO
;
IL Han CHOO
;
Won KIM
;
Jung Goo LEE
;
Myung Hun JUNG
;
Duk-In JON
;
Sung-Yong PARK
;
InKi SOHN
;
Moon-Doo KIM
;
Bo-Hyun YOON
;
Se-Hoon SHIM
Author Information
1. Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Korean Neuropsychiatric Association
2022;61(3):224-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents.
Methods:We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey.
Results:The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatment of choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, and monotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategies for depressive episodes in adolescents were a combination of MS and an AAP, monotherapy with MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for the depressive episodes in adolescents at high risk for bipolar disorder were a combination of MS and AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, and risperidone were selected as first-line medications for the treatment of depressive episodes in adolescents with bipolar disorder.
Conclusion:It is expected that the present KMAP-BP 2022: children and adolescents will give the direction and be usefully applied by clinicians to treat children and adolescents with bipolar disorders.
